Exhibit 99.1
Quotient Limited and hVIVO Announce Partnership to Support Wide-SpreadCOVID-19 Antibody Testing in the UK
JERSEY, Channel Islands, 11 May 2020(GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQCOVID-19 Antibody Microarray will be used by hVIVO to screen forSARS-CoV-2 antibodies(COVID-19). Quotient has entered into an exclusive contract with hVIVO, whereby Quotient is hVIVO’s exclusive supplier ofCOVID-19 antibody testing equipment, to supportCOVID-19 antibody testing in the UK.
hVIVO, based in London, UK, is a world leader in the testing of vaccines and antivirals using human challenge study models.
“We are delighted to exclusively partner with Quotient to bring fast and accurateCOVID-19 antibody testing to the UK. Open Orphan plc, via our subsidiary hVIVO, has industry leading scientific and laboratory capability and the MosaiQ™ system’s best in classCOVID-19 antibody testing performance makes the system a natural addition to ourstate-of-the-art virology laboratory in London. There is a clear demand forCOVID-19 antibody testing and we will be making testing available both as a standalone offering and will also utilize the testing capability to screen volunteers for our industry leading range of human challenge studies to ensure no disruption to our clients,” said Cathal Friel, Executive Chairman, hVIVO, part of Open Orphan plc.
“This collaboration marks a major milestone for our company, and we are proud to collaborate with an industry leader like hVIVO. Quotient has developed what we believe is a gold standard antibody microarray to help combat theCOVID-19 pandemic. This collaboration is uniquely positioned to leverage our combined expertise and help address the large need for antibody testing in the U.K. and beyond.” said Franz Walt, Chief Executive Officer of Quotient.
The MosaiQCOVID-19 Antibody Microarray was CE marked (certified to meet EU requirements) as of May 1, 2020 based on testing that demonstrated 100% sensitivity (ability to detectCOVID-19 antibodies) and 99.8% specificity (ability to rule out the presence ofCOVID-19 antibodies). The test is designed as a serological disease screen specific toCOVID-19. It detects the IgG and IgM antibodies that humans develop when infected bySARS-CoV-2.
About Quotient Limited
Building on 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. Quotient’s operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
About hVIVO, part of Open Orphan plc
Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. It has Europe’s only24-bedroom quarantine clinic with onsite virology lab in Queen Mary’s Hospital London. hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness ofCovid-19 in 2020. The Company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models.
Page 1/2
